Article
Gastroenterology & Hepatology
Neeraj Narula, Emily C. L. Wong, John K. Marshall, Jean-Frederic Colombel, Parambir S. Dulai, Walter Reinisch
Summary: For patients with moderate to severe biologic naive UC, infliximab and vedolizumab have similar efficacy in improving clinical symptoms, but infliximab has higher rates of corticosteroid-free clinical remission (CR) and endoscopic remission (ER) after 1 year of treatment.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY
(2022)
Article
Gastroenterology & Hepatology
A. Buisson, M. Nachury, M. Bazoge, C. Yzet, P. Wils, M. Dodel, D. Coban, B. Pereira, M. Fumery
Summary: Switching from intravenous to subcutaneous infliximab can reduce the long-term risk of relapse in patients with inflammatory bowel disease. Close monitoring and dose escalation should be recommended for patients receiving different doses.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS
(2023)
Article
Biochemistry & Molecular Biology
Jose M. Huguet, Victor Garcia-Lorenzo, Lidia Marti, Jose Maria Paredes, Jose Joaquin Ramirez, Miguel Pastor, Lucia Ruiz, Ana Sanahuja, Pilar Timoneda, Laura Sanchis, Gloria Alemany Perez, Marta Maia Bosca-Watts
Summary: This study evaluated the efficacy and safety of subcutaneous infliximab in patients with inflammatory bowel disease. The results showed that subcutaneous administration of infliximab has the potential to maintain treatment stability and increase drug levels. This is of great significance for the management of patients with inflammatory bowel disease.
Article
Gastroenterology & Hepatology
Laura E. Targownik, Charles N. Bernstein, Eric Benchimol, Gilaad G. Kaplan, Harminder Singh, Aruni Tennakoon, Zoann Nugent, Stephanie B. Coward, M. Ellen Kuenzig, Sanjay K. Murthy
Summary: Over the past two decades, the use of corticosteroids has decreased in both Crohn's disease and ulcerative colitis patients, with a more pronounced decline seen after 2007 in Crohn's disease. Potential reasons include the introduction and increasing use of biologic therapy for Crohn's disease and greater awareness of corticosteroid-related adverse events in IBD.
AMERICAN JOURNAL OF GASTROENTEROLOGY
(2021)
Article
Gastroenterology & Hepatology
Neasa Mc Gettigan, Aman Shah Afridi, Grace Harkin, Caroline Lardner, Stephen Patchett, Danny Cheriyan, Gavin Harewood, Karen Boland, Aoibhlinn O'Toole
Summary: The study aimed to identify optimal management strategies for anti-drug antibodies (ADAs) in patients receiving infliximab (IFX) to prevent therapy discontinuation. Results showed that increasing IFX dosage and adjusting combination therapy can lower rates of discontinuation of IFX, with significant cut-off values for ADA trough levels and important clinical outcomes identified through ROC curve analysis.
INTERNATIONAL JOURNAL OF COLORECTAL DISEASE
(2021)
Review
Pharmacology & Pharmacy
Alix Demaris, Ella S. K. Widigson, Johan F. K. F. Ilvemark, Casper Steenholdt, Jakob B. Seidelin, Wilhelm Huisinga, Robin Michelet, Linda B. S. Aulin, Charlotte Kloft
Summary: This review aims to analyze the population PK models of infliximab (IFX) in patients with ulcerative colitis (UC) and acute severe UC (ASUC), and assess the impact of disease activity on IFX PK. The results showed that there are still many gaps in the current research, such as a limited number of models specifically developed for UC patients, a lack of studies on severe UC patients, and a lack of evaluation of predictive performance for the models. Therefore, more comprehensive research and adequate reporting and evaluation of the models are needed for clinical application.
Article
Gastroenterology & Hepatology
Emily C. L. Wong, Shahin Merat, Cristina Monaco, Parambir S. Dulai, Vipul Jairath, John K. Marshall, Walter Reinisch, Neeraj Narula
Summary: In this post-hoc analysis, infliximab showed superior efficacy over tofacitinib for the treatment of moderate to severe biologic-naive UC. However, baseline characteristic mismatches persisted despite propensity score matching, and further studies are needed to confirm these findings.
DIGESTIVE DISEASES AND SCIENCES
(2023)
Article
Medicine, General & Internal
Mohammad Shehab, Mohamed Abu-Farha, Fatema Alrashed, Ahmad Alfadhli, Khazna Alotaibi, Abdullah Alsahli, Thangavel Alphonse Thanaraj, Arshad Channanath, Hamad Ali, Jehad Abubaker, Fahd Almulla
Summary: Patients with inflammatory bowel disease (IBD) receiving infliximab combination therapy had lower levels of SARS-CoV2 IgG, IgA, and neutralizing antibodies after BNT162b2 vaccination compared with healthy participants. However, most patients treated with infliximab combination therapy seroconverted after two doses of the vaccine.
JOURNAL OF CLINICAL MEDICINE
(2021)
Review
Medicine, General & Internal
Benjamin L. Gordon, Robert Battat
Summary: Therapeutic drug monitoring (TDM) is a useful strategy in ulcerative colitis (UC), particularly in acute severe UC (ASUC). While there is limited data available for the use of TDM of infliximab in ASUC, observational data suggest that higher serum infliximab concentrations and lower clearance are associated with better clinical outcomes and decreased rates of colectomy. However, more studies are needed to evaluate optimal dosing and TDM targets in this population.
JOURNAL OF CLINICAL MEDICINE
(2023)
Article
Gastroenterology & Hepatology
Rachel Nice, Neil Chanchlani, Harry Green, Claire Bewshea, Tariq Ahmad, James R. Goodhand, Timothy J. McDonald, Mandy H. Perry, Nicholas A. Kennedy
Summary: This study validates the positivity thresholds for drug-tolerant anti-infliximab and -adalimumab antibody assays, and finds that low-concentration anti-drug antibodies were associated with lower drug levels and treatment failure, particularly for adalimumab. It highlights the importance of deriving antibody positivity thresholds for accurate detection and treatment outcomes.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS
(2021)
Article
Gastroenterology & Hepatology
Robert Gilmore, Wei Lian Tan, Richard Fernandes, Yoon-Kyo An, Jakob Begun
Summary: This study found that upadacitinib may be a safe and effective salvage therapy for patients with steroid-refractory acute severe ulcerative colitis who have previously failed to respond to infliximab therapy. Prospective studies are needed to determine the safety and efficacy of upadacitinib use in this setting before routine use can be recommended.
JOURNAL OF CROHNS & COLITIS
(2023)
Article
Medicine, General & Internal
Marianne Kiszka-Kanowitz, Klaus Theede, Sandra Bohn Thomsen, Jacob Tveiten Bjerrum, Jorn Brynskov, Ida Benedikte Gottschalck, Elena Akimenko, Karen Lisa Hilsted, Anders Neumann, Signe Wildt, Lone Larsen, Jens Kristian Munk, Per Holger Ibsen, Huma Gul Rehana Janjua, Lise Lotte Gluud, Anette Mertz-Nielsen
Summary: The study suggests that combination therapy of low-dose azathioprine and allopurinol may be more effective in achieving steroid- and infliximab-free clinical remission in patients with moderate-to-severe UC compared to azathioprine monotherapy.
Article
Multidisciplinary Sciences
Renato Sablich, Maria Teresa Urbano, Marco Scarpa, Federico Scognamiglio, Alberto Paviotti, Edoardo Savarino
Summary: In this retrospective study, VDZ was found to be superior to IFX in terms of clinical remission, drug persistency, clinical response, and steroid-free remission for the treatment of moderate-to-severe ulcerative colitis. However, VDZ group required more drug optimization compared to the IFX group.
SCIENTIFIC REPORTS
(2023)
Article
Gastroenterology & Hepatology
Stefan Schreiber, Shomron Ben-Horin, Jaroslaw Leszczyszyn, Robert Dudkowiak, Adi Lahat, Beata Gawdis-Wojnarska, Aldis Pukitis, Marek Horynski, Katalin Farkas, Jaroslaw Kierkus, Maciej Kowalski, Sang Joon Lee, Sung Hyun Kim, Jee Hye Suh, Mi Rim Kim, Seul Gi Lee, Byong Duk Ye, Walter Reinisch
Summary: This study demonstrated the pharmacokinetic noninferiority of CT-P13 SC to CT-P13 IV, with comparable clinical remission rates between the two formulations.
Article
Pediatrics
Jennifer C. C. deBruyn, Kevan Jacobson, Wael El-Matary, Eytan Wine, Matthew W. Carroll, Caitlin Goedhart, Remo Panaccione, Iwona T. Wrobel, Hien Q. Huynh
Summary: The study evaluated the relationship between serum infliximab concentrations during induction and short-term clinical remission in children with ulcerative colitis. Higher infliximab concentrations prior to the second dose were associated with week 8 clinical remission. Young age and low body weight impact infliximab concentration, prompting the need for proactive adjustment in pediatric patients with ulcerative colitis.
FRONTIERS IN PEDIATRICS
(2021)
Letter
Rheumatology
Shintaro Akiyama, Shadi Hamdeh, Dejan Micic, Atsushi Sakuraba
ANNALS OF THE RHEUMATIC DISEASES
(2023)
Letter
Rheumatology
Shintaro Akiyama, Shadi Hamdeh, Dejan Micic, Atsushi Sakuraba
ANNALS OF THE RHEUMATIC DISEASES
(2023)
Article
Gastroenterology & Hepatology
Shintaro Akiyama, Jacob E. Ollech, Victoria Rai, Laura R. Glick, Yangtian Yi, Cindy Traboulsi, Joseph Runde, Russell D. Cohen, Kinga B. Skowron, Roger D. Hurst, Konstantin Umanskiy, Benjamin D. Shogan, Neil H. Hyman, Michele A. Rubin, Sushila R. Dalal, Atsushi Sakuraba, Joel Pekow, Eugene B. Chang, David T. Rubin
Summary: This study developed a new classification system for pouchitis based on the pattern of inflammation observed in pouches. It identified 7 different phenotypes and evaluated the contributing factors and prognosis of each phenotype. The study provides valuable insights for pouch management and future interventional studies.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY
(2022)
Article
Gastroenterology & Hepatology
Charles Muller, Akihiro Yamada, Sachie Ikegami, Haider Haider, Yuga Komaki, Fukiko Komaki, Dejan Micic, Atsushi Sakuraba
Summary: Serrated polyposis syndrome (SPS) is an underrecognized CRC predisposition syndrome with a higher risk of colorectal cancer, especially at the time of diagnosis. Early recognition, screening, and enhanced surveillance protocols are crucial in managing the elevated CRC risk in SPS patients.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY
(2022)
Article
Gastroenterology & Hepatology
Anthony Buisson, Lisa Cannon, Konstantin Umanskiy, Roger D. Hurst, Neil H. Hyman, Atsushi Sakuraba, Joel Pekow, Sushila Dalal, Russell D. Cohen, Bruno Pereira, David T. Rubin
Summary: Anti-TNF therapy was found to be the most effective medication in preventing endoscopic and clinical postoperative recurrence (POR) in Crohn's disease (CD). Combination therapy with anti-TNF agents and immunosuppressive drugs should be considered for patients previously exposed to anti-TNF before surgery.
INTESTINAL RESEARCH
(2022)
Article
Gastroenterology & Hepatology
Matthew Peller, Rajesh N. Keswani, Atsushi Sakuraba, Dejan Micic
Summary: The study found that a history of bariatric surgery is a risk factor for inadequate bowel preparation, particularly in patients who have undergone bypass surgery. Therefore, further efforts should be made to identify the appropriate bowel preparation regimen for these patients.
DIGESTIVE DISEASES AND SCIENCES
(2022)
Review
Gastroenterology & Hepatology
Atsushi Sakuraba, Alexander Luna, Dejan Micic
Summary: The meta-analysis showed that patients with immune-mediated inflammatory diseases have a reduced response to mRNA COVID-19 vaccines, especially those receiving anti-CD20 and anti-tumor necrosis factor therapy. These patients are less likely to achieve a serologic response even after completing the full vaccine series.
Review
Oncology
Atsushi Sakuraba, Alexander Luna, Dejan Micic
Summary: Patients with cancer, especially those with hematologic B-cell malignancies, have a lower serologic response to COVID-19 vaccines. Additional strategies for prophylaxis should be considered for cancer patients.
JOURNAL OF HEMATOLOGY & ONCOLOGY
(2022)
Review
Gastroenterology & Hepatology
Fares Ayoub, Matthew Odenwald, Dejan Micic, Sushila R. Dalal, Joel Pekow, Russell D. Cohen, David T. Rubin, Atsushi Sakuraba
Summary: This article systematically reviewed the effectiveness of vedolizumab for the management of perianal fistulizing CD and conducted a meta-analysis. The results showed that vedolizumab treatment led to healing of perianal fistulas in nearly one-third of the 198 patients included in the study. However, the lack of high-quality data and significant study heterogeneity highlight the need for future prospective studies to evaluate fistula healing in patients receiving anti-integrin therapy.
INTESTINAL RESEARCH
(2022)
Article
Medicine, General & Internal
Nathaniel A. Cohen, Dejan M. Micic, Atsushi Sakuraba
Summary: In this study, mental health disorders and smoking were independently associated with non-compliance to medication in predominantly adolescent, hospitalized pediatric CD patients. A multidisciplinary approach involving pediatric gastroenterologists, psychiatrists, and addiction specialists is needed to treat the underlying causes and improve adherence in these patients.
ANNALS OF MEDICINE
(2022)
Article
Gastroenterology & Hepatology
Shintaro Akiyama, Jacob E. Ollech, Cindy Traboulsi, Victoria Rai, Laura R. Glick, Yangtian Yi, Joseph Runde, Andrea D. Olivas, Christopher R. Weber, Russell D. Cohen, Kinga B. Skowron Olortegui, Roger D. Hurst, Konstantin Umanskiy, Benjamin D. Shogan, Michele A. Rubin, Sushila R. Dalal, Atsushi Sakuraba, Joel Pekow, Eugene B. Chang, John Hart, Neil H. Hyman, David T. Rubin
Summary: Our study aimed to assess how the histopathology of colectomy specimens predicts endoscopic pouch phenotypes in patients with UC. The results showed that deep inflammation was significantly associated with pouch fistulas, while terminal ileal involvement significantly increased the risk of afferent limb involvement.
DIGESTIVE DISEASES AND SCIENCES
(2022)
Review
Virology
Atsushi Sakuraba, Alexander Luna, Dejan Micic
Summary: The serologic response to the COVID-19 vaccine is extremely low in solid organ transplant recipients, and even the third dose has an insufficient response. Strategies for prophylaxis need to be developed for this vulnerable patient population.
Letter
Rheumatology
Shintaro Akiyama, Shadi Hamdeh, Dejan Micic, Atsushi Sakuraba
ANNALS OF THE RHEUMATIC DISEASES
(2023)
Letter
Rheumatology
Shintaro Akiyama, Shadi Hamdeh, Dejan Micic, Atsushi Sakuraba
ANNALS OF THE RHEUMATIC DISEASES
(2023)
Article
Gastroenterology & Hepatology
Maryam Zafer, Hui Zhang, Sujaata Dwadasi, Donald Goens, Raghavendra Paknikar, Sushila Dalal, Russell D. Cohen, Joel Pekow, David T. Rubin, Atsushi Sakuraba, Dejan Micic
Summary: The predictive factors for colectomy in severe ulcerative colitis include prior biologic exposure, need for inpatient salvage therapy, and younger age. A clinical predictive model based on admission data was developed to identify high-risk patients for one-year colectomy in adults hospitalized for severe UC.
CROHNS & COLITIS 360
(2022)